In my research group population pharmacokinetic-pharmacodynamic (PK-PD) models are developed to study the relationship between drug dose, plasma concentration and clinical outcome. By modelling and simulation support is given for the design of clinical trials. High-end mass-spectrometry equipment is used to quantify drugs in human material. State-of-the-art techniques are used to model the PK-PD relationship (nonlinear mixed-effects modelling, physiology-based PK, machine learning).
